Beck WT[au] - Search Results

Year	Number of Results
1972	1
1973	1
1975	1
1977	1
1979	1
1980	2
1982	2
1983	4
1984	2
1985	1
1986	4
1987	4
1988	5
1989	6
1990	8
1991	6
1992	5
1993	6
1994	6
1995	6
1996	6
1997	6
1998	4
1999	6
2000	4
2001	4
2002	3
2004	4
2005	2
2006	1
2007	4
2008	1
2009	2
2010	1
2011	5
2012	1
2013	2
2014	2
2016	1
2022	0

1

Antitopoisomerase drug action and resistance.

Nitiss JL, Beck WT. Nitiss JL, et al. Among authors: beck wt. Eur J Cancer. 1996 Jun;32A(6):958-66. doi: 10.1016/0959-8049(96)00056-1. Eur J Cancer. 1996. PMID: 8763336 Review. No abstract available.

2

Do anti-P-glycoprotein antibodies have a future in the circumvention of multidrug resistance?

Beck WT. Beck WT. J Natl Cancer Inst. 1991 Oct 2;83(19):1364-6. doi: 10.1093/jnci/83.19.1364. J Natl Cancer Inst. 1991. PMID: 1681109 Review. No abstract available.

3

Drug resistance associated with altered DNA topoisomerase II.

Beck WT, Danks MK, Wolverton JS, Kim R, Chen M. Beck WT, et al. Adv Enzyme Regul. 1993;33:113-27. doi: 10.1016/0065-2571(93)90012-3. Adv Enzyme Regul. 1993. PMID: 8395133 Review. No abstract available.

4

Altered DNA topoisomerase II in multidrug resistance.

Beck WT, Danks MK, Wolverton JS, Granzen B, Chen M, Schmidt CA, Bugg BY, Friche E, Suttle DP. Beck WT, et al. Cytotechnology. 1993;11(2):115-9. doi: 10.1007/BF00749000. Cytotechnology. 1993. PMID: 7764055 Review.

5

Cytotoxic signalling by inhibitors of DNA topoisomerase II.

Beck WT, Mo YY, Bhat UG. Beck WT, et al. Biochem Soc Trans. 2001 Nov;29(Pt 6):702-3. doi: 10.1042/0300-5127:0290702. Biochem Soc Trans. 2001. PMID: 11709058 Review.

6

Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.

Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R. Beck WT, et al. Cancer Res. 1996 Jul 1;56(13):3010-20. Cancer Res. 1996. PMID: 8674056 Review.

7

The cell biology of multiple drug resistance.

Beck WT. Beck WT. Biochem Pharmacol. 1987 Sep 15;36(18):2879-87. doi: 10.1016/0006-2952(87)90198-5. Biochem Pharmacol. 1987. PMID: 2888464 Review. No abstract available.

8

Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors.

Beck WT. Beck WT. Cancer Treat Rev. 1990 Dec;17 Suppl A:11-20. doi: 10.1016/0305-7372(90)90011-4. Cancer Treat Rev. 1990. PMID: 1982639 Review.

9

Circumvention of multidrug resistance with anti-P-glycoprotein antibodies: clinical potential or experimental artifact?

Beck WT. Beck WT. J Natl Cancer Inst. 1995 Jan 18;87(2):73-5. doi: 10.1093/jnci/87.2.73. J Natl Cancer Inst. 1995. PMID: 7707392 Review. No abstract available.

10

A role for Ubc9 in tumorigenesis.

Mo YY, Yu Y, Theodosiou E, Ee PL, Beck WT. Mo YY, et al. Among authors: beck wt. Oncogene. 2005 Apr 14;24(16):2677-83. doi: 10.1038/sj.onc.1208210. Oncogene. 2005. PMID: 15735760

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results